Buprenorphine for Opioid Use Disorder in Pregnancy Can Improve Outcomes

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on May 2, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, May 2, 2025 -- For mothers with opioid use disorder (OUD), treatment with buprenorphine in pregnancy is associated with improved maternal and infant outcomes, according to a study published online April 27 in JAMA Health Forum to coincide with the annual meeting of the Pediatric Academic Societies, held from April 24 to 28 in Honolulu.

Sunaya R. Krishnapura, from the Vanderbilt University School of Medicine in Nashville, Tennessee, and colleagues conducted a retrospective cohort study involving maternal-infant dyads enrolled from 20 weeks of estimated gestational age to six weeks postpartum between 2010 and 2021 to examine whether treatment of OUD with buprenorphine is associated with improved maternal and infant outcomes compared with no treatment.

Overall, 51.6 percent of the 14,463 maternal-infant dyads received buprenorphine treatment. The researchers found that compared with untreated dyads, dyads treated with buprenorphine had a significantly lower rate of adverse pregnancy outcomes (25.4 versus 30.8 percent). Lower rates of severe maternal morbidity (SMM) events (5.4 versus 6.9 percent), preterm births (14.1 versus 20.0 percent), and neonatal intensive care unit (NICU) admissions (15.2 versus 17.2 percent) were also seen for the treatment group. Those with buprenorphine treatment had a 5.1 percentage point lower probability of any adverse outcomes in adjusted analyses, including a 1.2, 1.7, and 5.3 percentage point lower probability of SMM, NICU admission, and preterm birth, respectively. To avoid an adverse pregnancy outcome, the number needed to treat was 20.

"We found that buprenorphine use in pregnancy was associated with improvements in pregnancy and infant outcomes, underscoring the need for OUD treatment expansion in the United States," the authors write.

One author disclosed ties to the publishing industry.

Abstract/Full Text

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-05-03 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords